Manufacturer of Controlled Substances; Notice of Registration, 5848 [2012-2585]
Download as PDF
<![CDATA[
5848
Federal Register / Vol. 77, No. 24 / Monday, February 6, 2012 / Notices
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–2581 Filed 2–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
17:27 Feb 03, 2012
Jkt 226001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 20, 2011, and
published in the Federal Register on
October 28, 2011, 76 FR 66994,
Research Triangle Institute, Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Marihuana (7360) .......................
Cocaine (9041) ...........................
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Cody
Laboratories, Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Cody Laboratories, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
VerDate Mar<15>2010
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
By Notice dated September 28, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62450, Cody
Laboratories, Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Dihydromorphine (9145) ...............
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–2582 Filed 2–3–12; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
Drug
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 6, 2012.
I
II
The Institute will manufacture
marihuana, and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Research Triangle Institute to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Research Triangle Institute
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
PO 00000
Frm 00094
Fmt 4703
Sfmt 9990
the basic classes of controlled
substances listed.
[FR Doc. 2012–2585 Filed 2–3–12; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 28, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62449,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Diphenoxylate (9170), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the listed controlled substance for sale
in bulk to its customers for formulation
into finished pharmaceuticals.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–2589 Filed 2–3–12; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 77, Number 24 (Monday, February 6, 2012)]
[Notices]
[Page 5848]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2585]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 20, 2011, and published in the Federal
Register on October 28, 2011, 76 FR 66994, Research Triangle Institute,
Hermann Building, East Institute Drive, P.O. Box 12194, Research
Triangle, North Carolina 27709, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Cocaine (9041)............................. II
------------------------------------------------------------------------
The Institute will manufacture marihuana, and cocaine derivatives
for use by their customers in analytical kits, reagents, and reference
standards as directed by the National Institute on Drug Abuse.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Research Triangle Institute to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Research Triangle Institute to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-2585 Filed 2-3-12; 8:45 am]
BILLING CODE 4410-09-P
